

Frequently Asked Questions

1. Where will the study occur?

These infusions will be performed at Infusion Associates' Grand Rapids, MI location in an isolated manner to protect our vulnerable patient population and our staff. They will be performed in a portable office with proper ventilation, ADA access that will be independent of the current infusion facility, and an ADA-compliant, private restroom. The portable center will be equipped with medical supplies and devices necessary to care for the patients. This equipment will NOT be shared with Infusion Associates' primary infusion center.

2. What is the purpose of the study?

To determine if an experimental drug can reduce the harmful effects of COVID-19 and help people stay out of the hospital.

3. What treatment will my patients receive?

As part of the study, your patient(s) will receive either the study drug OR a placebo, in addition to the monoclonal antibody therapy that has been approved for emergency use by the FDA.

4. Who qualifies for the study?

Patients who:

- Test positive for COVID-19 within the past 5 days
- Are at high risk for developing severe disease
- Patients 55 years and older
- Patients 18 years and above who are immunocompromised

5. What happens if a patient doesn't qualify for the study?

The patient may still receive standard of care therapy which includes monoclonal antibody therapy that has been approved for emergency use by the FDA. These patients will also be treated in the portable center.

6. How do I refer patients for this study?

We require a provider referral using our order form with a verified positive COVID-19 test within 5 days or less of their test. If a patient calls to inquire about participation, we will coordinate with their assigned provider similar to the process currently used with routine patients.

7. If I know someone that has tested COVID-19 positive and is interested in participating, how do I get them involved?

Please direct all interested parties to Mary Beth Readwin at (616) 655-1909.

8. **Will COVID-19 positive patients enter the infusion suite?**

No. We have a dedicated structure located outside the suite in our parking lot to care for only COVID-19 positive patients.

9. **How long will the study be offered?**

Until enrollment is reached. This is an international study with an enrollment goal of over 800 participants.